KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
12.9 nM 2.5 μM 9.3 μM 16.6 μM >100 μM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5T2lEPTB;Mz6yO|M2OiEQvF2= MWrTRW5ITVJ?
HuO-3N1 NFnMboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG1[IdbUUN3ME20MlE4OTR{IN88US=> M{HqRnNCVkeHUh?=
LAMA-84 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXuTWM2OD12LkW4OFY2KM7:TR?= NVPKN2pWW0GQR1XS
CAL-72 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorxTWM2OD13LkS4NFg1KM7:TR?= M3LUVnNCVkeHUh?=
LoVo M{HSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\vWGlEPTB;Nj65N|I{QSEQvF2= NH;HUmZUSU6JRWK=
HH MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfsTWM2OD16LkK3OlcyKM7:TR?= MY\TRW5ITVJ?
SK-MEL-3 M{DOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XYV2lEPTB;OD6yPFU4PSEQvF2= NELrO4ZUSU6JRWK=
KM12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTlwMkGxOFIh|ryP MnO2V2FPT0WU
NCI-H1437 NVi3WXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPJ[WdKSzVyPUmuPFA6PyEQvF2= Mn\nV2FPT0WU
NCI-H1838 M4i0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2TWZxUUN3ME2xNU4yQDZ3IN88US=> M4T4eHNCVkeHUh?=
J-RT3-T3-5 NXPWV|FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILsNY1KSzVyPUGxMlI1OTdizszN NXjObGgxW0GQR1XS
GOTO Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPQTWM2OD1zMT62PVk3KM7:TR?= MkLGV2FPT0WU
LB2241-RCC NI[zVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK2ZVBKSzVyPUGxMlcyQDZizszN MV3TRW5ITVJ?
ES7 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DwSWlEPTB;MUGuO|g5KM7:TR?= MXzTRW5ITVJ?
KP-N-YS NHvTUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF{Lk[zOVQh|ryP MWXTRW5ITVJ?
CAL-12T M3\aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e2bmlEPTB;MUOuOlE4KM7:TR?= NITzSnBUSU6JRWK=
COLO-684 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7PZmdKSzVyPUG0MlE2PjlizszN MkfoV2FPT0WU
DOK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W1WmlEPTB;MUWuN|MzQSEQvF2= NV7qUlV2W0GQR1XS
Hs-578-T M3TLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF3LkSxPFIh|ryP M3\DWHNCVkeHUh?=
D-423MG M1\5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G1bmlEPTB;MUWuOVI{PiEQvF2= NWG3ZoVqW0GQR1XS
DBTRG-05MG M4fHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF3Lk[xNVEh|ryP NE\pOWFUSU6JRWK=
VM-CUB-1 NFfZ[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4dFdKUUN3ME2xOU46QDR7IN88US=> NFvG[ZRUSU6JRWK=
KG-1 NHfrfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS0TWM2OD1zNj6wPVk3KM7:TR?= Mo[2V2FPT0WU
8305C M1jXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HhVGlEPTB;MU[uNVg5QSEQvF2= NX7YXXhZW0GQR1XS
HuH-7 M3mwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTBfZBKSzVyPUG2MlI3PzRizszN M3vs[HNCVkeHUh?=
LXF-289 M1XQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvUbXB{UUN3ME2xOk4zPzR5IN88US=> MXjTRW5ITVJ?
NCI-H1793 M4n5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zCNmlEPTB;MU[uOFcyOiEQvF2= MnTDV2FPT0WU
ChaGo-K-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELqXYlKSzVyPUG2MlY2PjhizszN NWfmPJpuW0GQR1XS
GCIY NFLWdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M362TGlEPTB;MU[uO|kxPSEQvF2= MVrTRW5ITVJ?
SK-MEL-28 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jISGlEPTB;MUeuNFQ4PSEQvF2= M1\hZXNCVkeHUh?=
NCI-SNU-1 NYDZTZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfIXI1KSzVyPUG3MlEzPjlizszN M3i4PHNCVkeHUh?=
CTB-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjLZVV[UUN3ME2xO{4zOjV7IN88US=> M4exUXNCVkeHUh?=
NCI-H82 M3zJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zvXGlEPTB;MUeuOFU4OyEQvF2= Mon1V2FPT0WU
HCC2998 NYfTb4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXCSVJKSzVyPUG3MlY4OzNizszN M4KzcHNCVkeHUh?=
NCI-H2030 NEf3XFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF6LkG5PVch|ryP NYnnVIRiW0GQR1XS
HuP-T3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65UVFKSzVyPUG4MlU5QDhizszN NXHnPZo1W0GQR1XS
697 NFm4WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPlXGdpUUN3ME2xPU4xOjBzIN88US=> NIHDSplUSU6JRWK=
MLMA M1P4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zsbmlEPTB;MUmuNFU2PyEQvF2= M3;ySnNCVkeHUh?=
HCC70 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;OblNKSzVyPUG5MlQ5QSEQvF2= NFK4b2xUSU6JRWK=
A704 M{DWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF7LkizNFUh|ryP M3f1TXNCVkeHUh?=
D-283MED MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHmTWM2OD1{MD61N|M6KM7:TR?= NUfQUWFRW0GQR1XS
U031 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHKUVVKSzVyPUKxMlE1QDlizszN NVK2VYoxW0GQR1XS
HSC-3 NFjyfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzSRmJKSzVyPUKxMlE5OzVizszN MXXTRW5ITVJ?
JVM-3 NInmNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jmfWlEPTB;MkKuOVA3KM7:TR?= NX;KOHluW0GQR1XS
Mewo NGq5NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HaPGlEPTB;MkKuOVA4OyEQvF2= MnTQV2FPT0WU
YH-13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4SGZzUUN3ME2yNk42OTJ|IN88US=> Mn\hV2FPT0WU
LB1047-RCC MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXLTWM2OD1{Mj61PFc6KM7:TR?= M4rtU3NCVkeHUh?=
HCC2157 NWX0N|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvid48yUUN3ME2yNk45ODV2IN88US=> M1vNcnNCVkeHUh?=
SNU-449 NVPNRY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ{Lki3OFgh|ryP MmmzV2FPT0WU
Ramos-2G6-4C10 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\1TWM2OD1{Mj65OkDPxE1? M4\uXHNCVkeHUh?=
CHL-1 NYe2XmJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnGXW5KSzVyPUKzMlczQTJizszN MUDTRW5ITVJ?
SK-MEL-30 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ2LkS2OlIh|ryP MoXTV2FPT0WU
PANC-08-13 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e1XWlEPTB;MkWuNFk{QCEQvF2= MVjTRW5ITVJ?
QIMR-WIL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\jN2hKSzVyPUK1MlE5PThizszN MWLTRW5ITVJ?
BFTC-905 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30VYRKSzVyPUK1MlU6PDRizszN M3TONHNCVkeHUh?=
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rwcGlEPTB;MkWuO|A2PSEQvF2= M37ETXNCVkeHUh?=
MDA-MB-415 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrV2lEPTB;Mk[uOVA{OyEQvF2= NIjsbXJUSU6JRWK=
GT3TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ4LkWzOFIh|ryP NX[5S4l4W0GQR1XS
DEL NWLFN2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ni[WlEPTB;Mk[uPFM2PiEQvF2= MkfDV2FPT0WU
KOSC-2 NHjrboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\lc4dKSzVyPUK2MlkxPzVizszN NFz1TWRUSU6JRWK=
RVH-421 NXjvPGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\tcolLUUN3ME2yO{4zQTJzIN88US=> MmryV2FPT0WU
EW-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH2TWM2OD1{Nz60N|A5KM7:TR?= NWD1RlREW0GQR1XS
639-V M{PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ5LkWxNVkh|ryP MV;TRW5ITVJ?
A2780 M4rNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\VcGtKSzVyPUK3MlY1OSEQvF2= NX3WbXpkW0GQR1XS
SW982 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\aTWM2OD1{Nz65NFUzKM7:TR?= NVPLT|dYW0GQR1XS
SW1710 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnpNmVKSzVyPUK4MlA6QDFizszN MnK1V2FPT0WU
HCC1569 NVjZWFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ6LkS4PVch|ryP M2TidHNCVkeHUh?=
MV-4-11 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MliyTWM2OD1{OD61O|M2KM7:TR?= MV\TRW5ITVJ?
BHT-101 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hZ45QUUN3ME2yPE43PTd{IN88US=> NX;MOGlmW0GQR1XS
Ca9-22 NIj4XWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\PWVRKSzVyPUK4MlcyPCEQvF2= MnnCV2FPT0WU
HAL-01 NVLRcGVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riN2lEPTB;MkiuO|YyPSEQvF2= NYjwSVdLW0GQR1XS
D-263MG M3XoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnWVm5KSzVyPUK5MlM1PCEQvF2= MmnWV2FPT0WU
NEC8 NV65UZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ7LkW1OFgh|ryP M4[5dnNCVkeHUh?=
EKVX NGLzV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iwN2lEPTB;M{GuOVg1PyEQvF2= NGrJUVhUSU6JRWK=
EM-2 NXG5d4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLIVZdkUUN3ME2zNU43OzB2IN88US=> M4f2ZnNCVkeHUh?=
MFM-223 M17nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWTJZtUUN3ME2zNU45ODl6IN88US=> MYPTRW5ITVJ?
SK-PN-DW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQTZNHUUN3ME2zNk4yPDB4IN88US=> NF\1R5FUSU6JRWK=
HuO9 NUjsN3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN{LkWyPFIh|ryP NYHzZlFGW0GQR1XS
MHH-PREB-1 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1cnF5UUN3ME2zNk43OjN2IN88US=> NH7BTm5USU6JRWK=
OVCAR-4 NGTiTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\4TGlEPTB;M{KuPFM3OyEQvF2= MVTTRW5ITVJ?
NCI-H1648 NV3JW2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;tdGlEPTB;M{KuPFY2OSEQvF2= NYDieGNjW0GQR1XS
MKN1 NI\aU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PiS2lEPTB;M{SuNVExOSEQvF2= M1fKUHNCVkeHUh?=
KYSE-450 NUDLSXdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\n[poxUUN3ME2zOE43PDR2IN88US=> NFfOWpJUSU6JRWK=
ES8 NYXwdmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37rdGlEPTB;M{SuPFk4PSEQvF2= MYTTRW5ITVJ?
MS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2OnZsUUN3ME2zOE46PTV2IN88US=> NYXxNoY4W0GQR1XS
HOP-92 NHLn[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1exRmlEPTB;M{WuPVI4PyEQvF2= MUHTRW5ITVJ?
SKG-IIIa NUfoOIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPzTWM2OD1|Nj6yOVYyKM7:TR?= M1j0R3NCVkeHUh?=
TE-11 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN4LkWyOFMh|ryP NYLYdHg6W0GQR1XS
SK-NEP-1 M1PxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZ[YpOUUN3ME2zO{43PzR2IN88US=> NHnsTW9USU6JRWK=
DB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN5LkmxPFUh|ryP MXPTRW5ITVJ?
IA-LM MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn1TWM2OD1|OD6wNlM6KM7:TR?= M4LJO3NCVkeHUh?=
COLO-829 NVnyVY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvnSGNKSzVyPUO4MlQyPTlizszN Mk\xV2FPT0WU
TGBC11TKB NI\iUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmwWYhMUUN3ME2zPU4yPDB6IN88US=> NFv0N|lUSU6JRWK=
CAL-51 Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z3fWlEPTB;NECuNFYyOiEQvF2= NHfBeldUSU6JRWK=
NCI-H2228 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfjTWM2OD12MD6zOlYzKM7:TR?= M{DuSHNCVkeHUh?=
C32 M3PEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTONIdyUUN3ME20NE41ODJ2IN88US=> M3LrWXNCVkeHUh?=
KU-19-19 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRyLke2PFMh|ryP M{H3e3NCVkeHUh?=
KNS-62 M{H1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzhZ|lbUUN3ME20NE45OzhzIN88US=> NHjPS5NUSU6JRWK=
FADU M4PnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBdZdKSzVyPUSxMlI2ODJizszN MX\TRW5ITVJ?
CAL-33 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfF[I5KSzVyPUSyMlY4PDlizszN M1G3bXNCVkeHUh?=
CHP-134 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR{Lki0PVYh|ryP NVHwb4ZlW0GQR1XS
HDLM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR{LkmwPFQh|ryP M2HvNHNCVkeHUh?=
NBsusSR MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWzRnZKSzVyPUSzMlA4OjVizszN MnfsV2FPT0WU
SW954 NUntPJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD12Mz6xNFU{KM7:TR?= MVnTRW5ITVJ?
HCC1806 NFv3UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\TTWM2OD12Mz60NVEh|ryP M{jSOnNCVkeHUh?=
VMRC-RCZ M2j3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR|LkS1PFYh|ryP M4S5NHNCVkeHUh?=
A549 M2fSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQfG5RUUN3ME20N{46OzFizszN NWHMN2VNW0GQR1XS
NKM-1 M1nEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWUGlEPTB;NEOuPVU2QCEQvF2= NH75XXdUSU6JRWK=
DMS-273 NIntboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nHdWlEPTB;NESuO|U3PyEQvF2= NHTGXZdUSU6JRWK=
TYK-nu NHXiVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR3LkGyN|Qh|ryP NW[wZZBwW0GQR1XS
KALS-1 NX7sd3RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLSTWM2OD12NT6xOFYh|ryP MlnMV2FPT0WU
A101D NETMPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3SSWJ5UUN3ME20OU41PDV4IN88US=> Mm\1V2FPT0WU
G-361 M1n6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPzTWM2OD12Nj6yNVM5KM7:TR?= NXn0SG1PW0GQR1XS
KARPAS-299 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH4TWM2OD12Nj6zOVE3KM7:TR?= Mkn1V2FPT0WU
RS4-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7EO|h1UUN3ME20Ok42PDJizszN M1rPOHNCVkeHUh?=
HT-1376 NYLGbGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XTcGlEPTB;NE[uO|QzPiEQvF2= MnLsV2FPT0WU
SK-N-AS NFXjOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln6TWM2OD12Nj63PFIzKM7:TR?= Mn;lV2FPT0WU
MG-63 M1\afmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR4LkmwN|Yh|ryP M1fWT3NCVkeHUh?=
EPLC-272H MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKzPVBKSzVyPUS2Mlk2ODNizszN MYTTRW5ITVJ?
BALL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\RTWM2OD12Nz64N|Ih|ryP MoPYV2FPT0WU
LCLC-97TM1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DweWlEPTB;NEiuNlAzKM7:TR?= NWnSbIdJW0GQR1XS
HO-1-N-1 NIqyOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInW[FlKSzVyPUS4Mlk3PzZizszN NUjJdHhoW0GQR1XS
MFE-280 M{\MOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR7LkS2NVch|ryP NHzHWnlUSU6JRWK=
NCI-H526 NXnM[29qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT3TWM2OD12OT64NVY{KM7:TR?= MV\TRW5ITVJ?
D-566MG NEjSSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD2XlhKSzVyPUS5MlkxQTZizszN M3nlfHNCVkeHUh?=
BB30-HNC M2jIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDxU|JrUUN3ME20PU46PDl6IN88US=> M2XGPHNCVkeHUh?=
SK-N-DZ MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0TWM2OD13MD6wOFgyKM7:TR?= M1LKV3NCVkeHUh?=
HepG2  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnVXFBkOTEEoN88US=> MUCyOEBp MojHZoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> M2LBWVI2PTJ5MUKz
HepG2  NELkUo5HfW6ldHnvckBCe3OjeR?= NF3xVncyOMLizszN NVrVb2Q{OjRiaB?= MoHLd5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> MljLNlU2OjdzMkO=
KATO III  NWHJPYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr5V4kzNjVxNT:3MlUh|ryP M4G1ZWROW09? MXzlcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ? M1nJUVI1QDRzN{G4
hTCEpi NYHhcoVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNNZVYOTBizszN M12xZWROW09? MVPwdoV3\W62czD0bIUh[3m2b4DheIhq[yCnZn\lZ5Qhd2ZiSGPWMVE> MlPzNlQ{PzB6M{W=
MCF10A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSyT5JpOTBizszN MmLVNlQhcA>? Ml\DSG1UVw>? NXr4ZlF{eG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=> NUXIc5NIOjRzNUC1PVU>
HL-60  NYTlNnJxTnWwY4Tpc44hSXO|YYm= M2fVVlExKM7:TR?= MVOwMlUhcA>? MXvEUXNQ NXXMPYE5emWmdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMtMg NE\ReHgzOzl|NESxNS=>
MCF-7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj1PHEyNTFyMN88US=> NVPhc5RZOjRiaB?= M3XxR2ZDWw>? MoK1bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MVuyN|E5PTN2Nx?=
HeLa  NGDDV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxMVExOM7:TR?= MWmyOEBp M3fPOGZDWw>? MYLpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MYSyN|E5PTN2Nx?=
SH-SY5Y NHfOWVdHfW6ldHnvckBCe3OjeR?= M{HofFExyqEQvF5CpC=> MWKyOEBp Mly4bY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MmX0NlI3Ojd{OUS=
IMR-32 MnnYSpVv[3Srb36gRZN{[Xl? Mn31NVDDqM7:TdMg MUWyOEBp M{fWVYlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| MUKyNlYzPzJ7NB?=
A549 NG\ubFNHfW6ldHnvckBCe3OjeR?= MmjXNVDDqM7:TdMg M135VVEhcA>? NWTnNJBOe3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=> M2PRe|IzPTV7M{Kx
T47D  M1npUGZ2dmO2aX;uJGF{e2G7 NFPi[3QzOMLibV2= NXvrXm9DOjRiaB?= MoPnSG1UVw>? MlP5dJJmfmWwdIOgTXIucW6mdXPl[EBl\We{YXTheIlwdiCxZjDJ{tpD|rF? MX6yNVE1PDhyNR?=
A29 MEF M4nrbmZ2dmO2aX;uJGF{e2G7 M4W4OFExyqEQvF5CpC=> MlXxNYg> NVyxR2M4[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? M2m2elIxODV|N{ix
MDA-MB-453  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq1MVQxKM7:TR?= MmWxO|IhcA>? MXPJR|UxKG:oIEGwJO69VQ>? M4S5bVIxODV|N{ix
PC-3 NF\xe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjQe5kzPS12MDFOwG0> NH\3NY84OiCq MonsTWM2OCCxZjCxNEDPxE1? NVXadotMOjByNUO3PFE>

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:[1]
+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:[1]
+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method: U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO and 47.5% PEG300 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID